SFJ Pharmaceuticals is declaring the final victory in its legal tussle with PhaseBio over a blood thinner reversal agent. Backed by Abingworth and Blackstone, San Diego-based SFJ first inked a deal two years ago to provide PhaseBio with up to $120 million in clinical development funding in exchange for payments…
Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug
